> Contact
> Homepage
> Site map
> Links

About HIFU
About Ablatherm
  Overview
  History
  Treatment Procedure
  Follow-up
  Reference List
Clinical Information
Clinical Results
Clinical Trials


Published Abstracts
& Articles
Video Clips
 You are here : Physicians > HIFU - Ablatherm > About Ablatherm > History
In 1989, INSERM unit U281(French National Institute for Health and Medical Research), the Urology service of the Edouard Herriot Hospital Lyon, France and EDAP Technomed joined efforts and initiated a research project in France. This project was to develop an efficient and minimally invasive treatment for localized prostate cancer (stages T1-T2). After ten years of development, the Ablatherm was CE marked (European approval) and the FDA gave approval for the United States to conduct a clinical study.

Today thousands of prostate cancer patients have been treated in several European centers.

The Ablatherm is approved for marketing and distribution in Europe, Canada, Australia, Russia and South Korea.

® Ablatherm is aregistered trademark of EDAP.
© Copyright 2007 EDAP. All rights reserved.